SPHINX 是 SRPK1 的选择性抑制剂，IC50 值为 0.58 μM。SPHINX 有效地减少体内脉络膜新生血管 (CNV)。SPHINX 可用于老年性黄斑变性的研究。
| Cas No. | 848057-98-7 |
| 分子式 | C17H17F3N2O3 |
| 分子量 | 354.32 |
| 溶解度 | DMSO : 50 mg/mL (141.12 mM; ultrasonic and warming and heat to 60°C) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 0.58 μM (SRPK1)[1] SPHINX is a selectiveSRPK1inhibitor with anIC50value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1]. SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1]. Western Blot Analysis[1] | Cell Line: | ARPE-19 cell line | | Concentration: | 10 μM | | Incubation Time: | 2 hours | | Result: | Blocked EGF-induced phosphorylation of SRSF1 and SRSF2. |
SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1]. | Animal Model: | C57/B6 mice with laser-induced CNV[1] | | Dosage: | 10 ng | | Administration: | Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 | | Result: | Significantly reduced neovascular growth compared with saline-injected controls. |
| Animal Model: | Norway Brown rats with laser-induced choroidal neovascularization[1] | | Dosage: | 25 ng (10 ng/uL) | | Administration: | Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 | | Result: | Significantly reduced the CNV area compared with saline injected controls. |
|
